Pub Date : 2016-07-07DOI: 10.4172/2167-0889.1000I102
L. Rodríguez-Fragoso
Figure 1: Microscopic images show the potential chemopreventive effect of gallic acid. Preneoplastic lesions were developed in rats by administration of a single dose of DEN (200 mg/Kg i.p) and CCl4 (2 mL/kg i.p.) during two weeks. Preneoplastic lesions showed the presence of microscopical small-cell dysplastic focus characterized by loss of liver tissue architecture, changes in nuclear morphology, cellular pleomorphism and cell mitosis (arrows). The gallic acid (50 mg/kg p.o.) was given during five weeks previous to the induction of preneoplastic lesions. Animals pretreated with gallic acid maintained the morphological architecture of liver and no cells in mitosis were observed. In the last decades, several studies have shown the chemopreventive potential of different polyphenols in cancer [1]. Particularly, the gallic acid have shown possess several protective properties anti-cancer as anti-proliferative, pro-apoptotic and anti-tumorigenic effects in vitro and in vivo models [2]. Gallic acid has shown to have a significant chemopreventive effect on development of hepatic preneoplastic lesions in rats. Gallic acid maintains the organization of liver tissue and avoids the development of changes in nuclear morphology, reduces the cellular pleomorphism and the number of cells in mitosis (Figure 1).
图1:显微镜图像显示没食子酸潜在的化学预防作用。大鼠在两周内给予单剂量DEN (200 mg/Kg i.p)和CCl4 (2 mL/ Kg i.p)，形成肿瘤前病变。肿瘤前病变表现为显微镜下的小细胞发育不良灶，其特征是肝组织结构丧失，核形态改变，细胞多形性和细胞有丝分裂(箭头)。没食子酸(50 mg/kg p.o.)在诱导肿瘤前病变前5周给予。经没食子酸预处理的动物肝脏形态结构保持不变，未见有丝分裂细胞。在过去的几十年里，一些研究显示了不同多酚在癌症中的化学预防潜力[1]。特别是，没食子酸在体外和体内模型中显示出抗增殖、促凋亡和抗肿瘤等多种抗癌保护特性[2]。没食子酸已被证明对大鼠肝脏肿瘤前病变的发展具有显著的化学预防作用。没食子酸维持肝组织的组织，避免核形态变化的发展，减少细胞的多形性和有丝分裂中的细胞数量(图1)。
{"title":"Gallic Acid may have the Potential to Preventing the Development of Preneoplastic Lesions in Liver","authors":"L. Rodríguez-Fragoso","doi":"10.4172/2167-0889.1000I102","DOIUrl":"https://doi.org/10.4172/2167-0889.1000I102","url":null,"abstract":"Figure 1: Microscopic images show the potential chemopreventive effect of gallic acid. Preneoplastic lesions were developed in rats by administration of a single dose of DEN (200 mg/Kg i.p) and CCl4 (2 mL/kg i.p.) during two weeks. Preneoplastic lesions showed the presence of microscopical small-cell dysplastic focus characterized by loss of liver tissue architecture, changes in nuclear morphology, cellular pleomorphism and cell mitosis (arrows). The gallic acid (50 mg/kg p.o.) was given during five weeks previous to the induction of preneoplastic lesions. Animals pretreated with gallic acid maintained the morphological architecture of liver and no cells in mitosis were observed. In the last decades, several studies have shown the chemopreventive potential of different polyphenols in cancer [1]. Particularly, the gallic acid have shown possess several protective properties anti-cancer as anti-proliferative, pro-apoptotic and anti-tumorigenic effects in vitro and in vivo models [2]. Gallic acid has shown to have a significant chemopreventive effect on development of hepatic preneoplastic lesions in rats. Gallic acid maintains the organization of liver tissue and avoids the development of changes in nuclear morphology, reduces the cellular pleomorphism and the number of cells in mitosis (Figure 1).","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"29 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2016-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79478036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-06-21DOI: 10.4172/2167-0889.1000196
Rodriguez Fragoso, Alvarez Ayala, García Vazquez, J. ReyesEsparza
Background and Objective: Liver disease chronicity leads to the appearance of fibrosis, cirrhosis, and eventually cancer. For this reason, it is important to research new fibrosis therapies. The use of genistein as a hepatoprotective agent has been studied, but its mechanism of action is unknown. The aim of this work was to evaluate the role of genistein as a fibrosis treatment and its possible mechanism of action through CCl4-induced inhibition of EGFR in rat specimens. Methods: Hepatic fibrosis was brought about by chronic administration of CCl4 to rats. Animals with fibrosis were treated with 1 mg/kg genistein. To evaluate the hepatoprotection of genistein on liver fibrosis, we made a histopathological analysis using both HE PCNA positive cells were reduced in this group. We observed liver functionality improvement in those animals with fibrosis that were treated with genistein. Conclusion: Genistein produces hepatoprotection through modulating the expression and phosphorylation of EGFR in experimental fibrosis.
{"title":"Genistein Produces Hepatoprotection through Modulating EGFR Expression and Phosphorylation in Experimental Fibrosis","authors":"Rodriguez Fragoso, Alvarez Ayala, García Vazquez, J. ReyesEsparza","doi":"10.4172/2167-0889.1000196","DOIUrl":"https://doi.org/10.4172/2167-0889.1000196","url":null,"abstract":"Background and Objective: Liver disease chronicity leads to the appearance of fibrosis, cirrhosis, and eventually cancer. For this reason, it is important to research new fibrosis therapies. The use of genistein as a hepatoprotective agent has been studied, but its mechanism of action is unknown. The aim of this work was to evaluate the role of genistein as a fibrosis treatment and its possible mechanism of action through CCl4-induced inhibition of EGFR in rat specimens. Methods: Hepatic fibrosis was brought about by chronic administration of CCl4 to rats. Animals with fibrosis were treated with 1 mg/kg genistein. To evaluate the hepatoprotection of genistein on liver fibrosis, we made a histopathological analysis using both HE PCNA positive cells were reduced in this group. We observed liver functionality improvement in those animals with fibrosis that were treated with genistein. Conclusion: Genistein produces hepatoprotection through modulating the expression and phosphorylation of EGFR in experimental fibrosis.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"65 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2016-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85712925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Hepatocellular carcinoma is commonly seen in chronic liver disease patients due to hepatitis B or C infection. Melena and haematemesis are the common gastrointestinal symptoms due to intraluminal haemorrhage. Surgical resection is the treatment of choice. Case presentation: We report a case of hepatocellular carcinoma presenting as gastric outlet obstruction in a 64 years male with chronic hepatitis B virus infection. Hepatocellular carcinoma was detected during evaluation for gastric outlet obstruction. Intra-operatively there was no invasion to the duodenum; rather there was extrinsic compression and adhesions around the duodenum. Patient underwent successful right posterior sectionectomy. Conclusion: Hepatocellular carcinoma presenting as gastric outlet obstruction is rare and curative surgery is possible in selected patients.
{"title":"A Typical Presentation of Hepatocellular Carcinoma","authors":"Chakravarty Kd, Samantaray Sp, Vishwanath Rs, Shashikala, Kumar Acp","doi":"10.4172/2167-0889.1000199","DOIUrl":"https://doi.org/10.4172/2167-0889.1000199","url":null,"abstract":"Introduction: Hepatocellular carcinoma is commonly seen in chronic liver disease patients due to hepatitis B or C infection. Melena and haematemesis are the common gastrointestinal symptoms due to intraluminal haemorrhage. Surgical resection is the treatment of choice. Case presentation: We report a case of hepatocellular carcinoma presenting as gastric outlet obstruction in a 64 years male with chronic hepatitis B virus infection. Hepatocellular carcinoma was detected during evaluation for gastric outlet obstruction. Intra-operatively there was no invasion to the duodenum; rather there was extrinsic compression and adhesions around the duodenum. Patient underwent successful right posterior sectionectomy. Conclusion: Hepatocellular carcinoma presenting as gastric outlet obstruction is rare and curative surgery is possible in selected patients.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"40 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2016-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83817144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-20DOI: 10.4172/2167-0889.C1.006
Nada Eldomiaty
D Liver Transplantation (DLT) started in 1995, using a donor liver with familial amyloid polyneuropathy (FAP), then increasing the pool of donors. Our Center started DLT in 2001; however cases of acquired amyloid neuropathy are increasingly being recognized following this procedure. Also our Center experience showed that the onset of FAP symptoms occurs earlier than expected. Several papers described clinical cases of acquired FAP developing 5 to 9 years after DLT. From 2001 to 2011 we have done 1078 liver transplants; we carried out 262 domino transplantations. All receptors transplanted between 2001 and 2011, were evaluated. All of them were observed and had clinical, histopathologic (salivary gland biopsy) and electrophysiologic evaluation. The symptomatic group started with sensory complaints involving their feet 4 to 10 years after DLT; three of those patients have been retransplanted to halt FAP progression and their clinical and paraclinical improvement is described. Five other patients are in the waiting list for retransplant. Patients with FAP acquired by transplantation are candidates for liver retransplantation to minimize the progression of symptoms. Liver retransplantation is considered to be a high-risk procedure but so far the results have been favorable.
{"title":"Recurrence of hepatocellular carcinoma after living donor liver transplantation (single center experience)","authors":"Nada Eldomiaty","doi":"10.4172/2167-0889.C1.006","DOIUrl":"https://doi.org/10.4172/2167-0889.C1.006","url":null,"abstract":"D Liver Transplantation (DLT) started in 1995, using a donor liver with familial amyloid polyneuropathy (FAP), then increasing the pool of donors. Our Center started DLT in 2001; however cases of acquired amyloid neuropathy are increasingly being recognized following this procedure. Also our Center experience showed that the onset of FAP symptoms occurs earlier than expected. Several papers described clinical cases of acquired FAP developing 5 to 9 years after DLT. From 2001 to 2011 we have done 1078 liver transplants; we carried out 262 domino transplantations. All receptors transplanted between 2001 and 2011, were evaluated. All of them were observed and had clinical, histopathologic (salivary gland biopsy) and electrophysiologic evaluation. The symptomatic group started with sensory complaints involving their feet 4 to 10 years after DLT; three of those patients have been retransplanted to halt FAP progression and their clinical and paraclinical improvement is described. Five other patients are in the waiting list for retransplant. Patients with FAP acquired by transplantation are candidates for liver retransplantation to minimize the progression of symptoms. Liver retransplantation is considered to be a high-risk procedure but so far the results have been favorable.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76150333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-20DOI: 10.4172/2167-0889.1000I101
B. Sanei
{"title":"Portal Cavernoma as a Complication of Liver Hydatid Cyst","authors":"B. Sanei","doi":"10.4172/2167-0889.1000I101","DOIUrl":"https://doi.org/10.4172/2167-0889.1000I101","url":null,"abstract":"","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"8 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2016-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80383287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-03-07DOI: 10.4172/2167-0889.1000194
À. Escorsell, F. Torres, M. VegaCatalina, A. Mas, J. Ríos, M. Guevara
Aim: The present study was aimed at the early identification of the prognostic factors for 30-day mortality in acutely decompensated cirrhotic patients. Methods: Logistic regression models were used to study the predictors of mortality. Variables significant on univariate testing were included for the multivariate analysis. ROC curves were constructed. The model used retrospective data from 228 patients; and was prospectively validated among 64 patients from the Hospital Clinic: internal validation and 90 patients from Hospital Gregorio Maranon: external validation. Results: The model identified age at admission, serum concentrations of bilirubin, creatinine and sodium, and INR obtained 2 to 8 days after admission as predictors of death in this population. The resulting risk score was highly accurate: AUROC: 0.9150, 95%CI: 0.8509-0.9790 also in the internal and external validation series, but not better that the most widely used scores in hepatology: MELD: 0.8335, 95%CI: 0.7486-0.9184, MELD-Na: 0.8565, 95%CI: 0.7774-0.9356, iMELD: 0.8972, 95%CI: 0.8297-0.9648 and MESO Index: 0.8464, 95%CI: 0.7656-0.9272. The cutoff levels: LR+, LR- of the new score, MELD and MELD-Na that best predicted 30 days mortality were -0.09: 38.6, 0.51, 28: 16.7, 0.42 and 47: 12, 0.7, respectively. Conclusions: MELD, as well as new, more complicated and scanty used scores, obtained 2 to 8 days after admission allows the early and easy identification of patients with an acute decompensation of cirrhosis at high-risk of death on short-term follow-up. These scores may represent a useful tool to select the population suitable for studies to evaluate the efficacy of new therapies and stratify patients in randomized trials.
{"title":"Short-term Survival in Acutely Decompensated Cirrhotic Patients","authors":"À. Escorsell, F. Torres, M. VegaCatalina, A. Mas, J. Ríos, M. Guevara","doi":"10.4172/2167-0889.1000194","DOIUrl":"https://doi.org/10.4172/2167-0889.1000194","url":null,"abstract":"Aim: The present study was aimed at the early identification of the prognostic factors for 30-day mortality in acutely decompensated cirrhotic patients. Methods: Logistic regression models were used to study the predictors of mortality. Variables significant on univariate testing were included for the multivariate analysis. ROC curves were constructed. The model used retrospective data from 228 patients; and was prospectively validated among 64 patients from the Hospital Clinic: internal validation and 90 patients from Hospital Gregorio Maranon: external validation. Results: The model identified age at admission, serum concentrations of bilirubin, creatinine and sodium, and INR obtained 2 to 8 days after admission as predictors of death in this population. The resulting risk score was highly accurate: AUROC: 0.9150, 95%CI: 0.8509-0.9790 also in the internal and external validation series, but not better that the most widely used scores in hepatology: MELD: 0.8335, 95%CI: 0.7486-0.9184, MELD-Na: 0.8565, 95%CI: 0.7774-0.9356, iMELD: 0.8972, 95%CI: 0.8297-0.9648 and MESO Index: 0.8464, 95%CI: 0.7656-0.9272. The cutoff levels: LR+, LR- of the new score, MELD and MELD-Na that best predicted 30 days mortality were -0.09: 38.6, 0.51, 28: 16.7, 0.42 and 47: 12, 0.7, respectively. Conclusions: MELD, as well as new, more complicated and scanty used scores, obtained 2 to 8 days after admission allows the early and easy identification of patients with an acute decompensation of cirrhosis at high-risk of death on short-term follow-up. These scores may represent a useful tool to select the population suitable for studies to evaluate the efficacy of new therapies and stratify patients in randomized trials.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"1 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2016-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82195265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-02-11DOI: 10.4172/2167-0889.1000193
N. Majethia, M. Patil, A. Kalgutkar
The day has not arrived when predictive value of liver disease can be given like many laboratory tests. Autopsy studies provide us with useful baseline data to start a step towards achieving good morphological accuracy. The present study compromised of 118 cases of cirrhosis detected from the period January 2008 to December 2013. 3960 autopsies done during this period were scrutinized and 824 cases had liver pathology. Out of the 824 cases 118 had cirrhosis as the liver pathology, which makes incidence of cirrhosis at autopsy as 14.3% of all liver pathology, which shows a decreasing incidence of cirrhosis which may be due decrease in autopsy rate over the years, the reasons for the continuing decline are complex and include attitudes toward autopsies of hospital administrative staff, medical staff, and family members and also because of increase in diagnosis by liver biopsy and introduction of antifibrotic therapy.
{"title":"A Histo-Pathological Study of Liver in 118 Cases of Cirrhosis","authors":"N. Majethia, M. Patil, A. Kalgutkar","doi":"10.4172/2167-0889.1000193","DOIUrl":"https://doi.org/10.4172/2167-0889.1000193","url":null,"abstract":"The day has not arrived when predictive value of liver disease can be given like many laboratory tests. Autopsy studies provide us with useful baseline data to start a step towards achieving good morphological accuracy. The present study compromised of 118 cases of cirrhosis detected from the period January 2008 to December 2013. 3960 autopsies done during this period were scrutinized and 824 cases had liver pathology. Out of the 824 cases 118 had cirrhosis as the liver pathology, which makes incidence of cirrhosis at autopsy as 14.3% of all liver pathology, which shows a decreasing incidence of cirrhosis which may be due decrease in autopsy rate over the years, the reasons for the continuing decline are complex and include attitudes toward autopsies of hospital administrative staff, medical staff, and family members and also because of increase in diagnosis by liver biopsy and introduction of antifibrotic therapy.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"20 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2016-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89390399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-18DOI: 10.4172/2167-0889.1000191
Xiaohui Wang, Jiang-yan Liu, Gang Chen, Yu Li, Yumin Li
Hepatocellular carcinoma (HCC) is relatively common worldwide. Until a few years ago skeletal involvement from HCC was rarely diagnosed. Thanks to novel imaging techniques and multidisciplinary treatment approaches, the overall survival in HCC patients has prolonged, and bone involvement has significantly increased currently. This short review summaries the value of bone scintigraphy in patients with hepatocellular carcinoma.
{"title":"Early Detection of Metastases by Bone Scintigraphy in Patients with Hepatocellular Carcinoma","authors":"Xiaohui Wang, Jiang-yan Liu, Gang Chen, Yu Li, Yumin Li","doi":"10.4172/2167-0889.1000191","DOIUrl":"https://doi.org/10.4172/2167-0889.1000191","url":null,"abstract":"Hepatocellular carcinoma (HCC) is relatively common worldwide. Until a few years ago skeletal involvement from HCC was rarely diagnosed. Thanks to novel imaging techniques and multidisciplinary treatment approaches, the overall survival in HCC patients has prolonged, and bone involvement has significantly increased currently. This short review summaries the value of bone scintigraphy in patients with hepatocellular carcinoma.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"111 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2016-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80421360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.4172/2167-0889.1000135
Pratika Y Hern, Alex, er Pedroza-Gonzalez, L. V. D. Laan, M. Hoogduijn, M. Peppelenbosch, Q. Pan
Colorectal Cancer (CRC) is the third most common cancer in the world. CRC tends to metastasize to the liver, which may occur in 20% to 70% of patients and represents the major cause of death. Mesenchymal Stem/stromal cells (MSCs) have shown to be able to migrate to CRC site and play an important role in tumor progression. We have previously identified a resident MSC population in the liver. Therefore, this study aims to investigate whether there is infiltration of MSCs into patient CRC Liver Metastasis (CRC-LM) and their potential effects on tumor cell growth. By culturing resected patient CRC-LM tissue, we observed the emerging of fibroblast-like cells. Further phenotype and functional characterization confirmed their bonafide MSCs features. In situ staining with a well-established MSCs marker showed a significant enrichment of candidate MSCs in patient CRC-LM, particularly the tumor-stromal area. Moreover, MSCs secreted trophic factors significantly increased colony formation and growth of a metastatic CRC cell line. In summary, we found infiltration and enrichment of MSCs in CRC-LM patient, which could in turn nourish tumor cells.
{"title":"Mesenchymal Stem/Stromal Cells Exert Trophic Effect on Colorectal Cancer Metastasis to the Liver","authors":"Pratika Y Hern, Alex, er Pedroza-Gonzalez, L. V. D. Laan, M. Hoogduijn, M. Peppelenbosch, Q. Pan","doi":"10.4172/2167-0889.1000135","DOIUrl":"https://doi.org/10.4172/2167-0889.1000135","url":null,"abstract":"Colorectal Cancer (CRC) is the third most common cancer in the world. CRC tends to metastasize to the liver, which may occur in 20% to 70% of patients and represents the major cause of death. Mesenchymal Stem/stromal cells (MSCs) have shown to be able to migrate to CRC site and play an important role in tumor progression. We have previously identified a resident MSC population in the liver. Therefore, this study aims to investigate whether there is infiltration of MSCs into patient CRC Liver Metastasis (CRC-LM) and their potential effects on tumor cell growth. By culturing resected patient CRC-LM tissue, we observed the emerging of fibroblast-like cells. Further phenotype and functional characterization confirmed their bonafide MSCs features. In situ staining with a well-established MSCs marker showed a significant enrichment of candidate MSCs in patient CRC-LM, particularly the tumor-stromal area. Moreover, MSCs secreted trophic factors significantly increased colony formation and growth of a metastatic CRC cell line. In summary, we found infiltration and enrichment of MSCs in CRC-LM patient, which could in turn nourish tumor cells.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"111 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79304764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.4172/2167-0889.1000139
K. Nielsen, Van der Sluis Wb, H. Scheffer, M. Meijerink, Comans Efi, B. Slotman, S. Meijer, van den Tol Mp, Haasbeek Cja
Background: Stereotactic Ablative Radiotherapy (SABR) is a non-invasive treatment option for patients with Colorectal Liver Metastases (CRLM) ineligible for resection or thermal ablation. The aim of our study was to evaluate local control, disease progression, toxicity, complications and survival after SABR of CRLM. We also discuss the place of SABR in the treatment algorithm of CRLM. Methods: Patients with CRLM, ineligible for resection or thermal ablation and suitable for SABR, were included in our database and retrospectively analyzed. Patients with oligometastases <5 cm without the presence of other organs in the target area are eligible for SABR. Follow-up imaging was conducted at 3 and 6 months following SABR and 6-monthly thereafter. Total delivered dose per lesion was 54-60 Gy, divided over 3-12 fractions, depending on the dose constraints of normal tissues. Results: Ten patients with 13 lesions were treated with SABR. Complete local control was achieved in eight patients with 11 lesions, with a median follow-up of 20.4 months (range 7-38). Two patients showed possible local progressive disease after 12 and 25 months. No toxicity > grade 2 as a result of treatment was reported. Eight patients had died at time of analysis; median survival was 26 months. Conclusion: SABR of CRLM is safe, feasible and effective in achieving local control in patients ineligible for resection or thermal ablation. Although SABR is currently offered in a late and often palliative stage, it deserves a higher profile as a possible local treatment option and its place in the treatment algorithm should be re-evaluated.
{"title":"Stereotactic Ablative Radiotherapy to Treat Colorectal Liver Metastases: Ready for Prime-Time?","authors":"K. Nielsen, Van der Sluis Wb, H. Scheffer, M. Meijerink, Comans Efi, B. Slotman, S. Meijer, van den Tol Mp, Haasbeek Cja","doi":"10.4172/2167-0889.1000139","DOIUrl":"https://doi.org/10.4172/2167-0889.1000139","url":null,"abstract":"Background: Stereotactic Ablative Radiotherapy (SABR) is a non-invasive treatment option for patients with Colorectal Liver Metastases (CRLM) ineligible for resection or thermal ablation. The aim of our study was to evaluate local control, disease progression, toxicity, complications and survival after SABR of CRLM. We also discuss the place of SABR in the treatment algorithm of CRLM. Methods: Patients with CRLM, ineligible for resection or thermal ablation and suitable for SABR, were included in our database and retrospectively analyzed. Patients with oligometastases <5 cm without the presence of other organs in the target area are eligible for SABR. Follow-up imaging was conducted at 3 and 6 months following SABR and 6-monthly thereafter. Total delivered dose per lesion was 54-60 Gy, divided over 3-12 fractions, depending on the dose constraints of normal tissues. Results: Ten patients with 13 lesions were treated with SABR. Complete local control was achieved in eight patients with 11 lesions, with a median follow-up of 20.4 months (range 7-38). Two patients showed possible local progressive disease after 12 and 25 months. No toxicity > grade 2 as a result of treatment was reported. Eight patients had died at time of analysis; median survival was 26 months. Conclusion: SABR of CRLM is safe, feasible and effective in achieving local control in patients ineligible for resection or thermal ablation. Although SABR is currently offered in a late and often palliative stage, it deserves a higher profile as a possible local treatment option and its place in the treatment algorithm should be re-evaluated.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"114 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86286820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：